The Effect of Virtual Reality on Chemotherapy-Associated Stress (Cortisol Value), Anxiety, and Pain Symptoms of Mastectomy Patients: A Randomized Controlled Pilot Study.

Cancer NursApr 2, 2025 (epub)

Vesile Eskici İlgin, Ayşegül Yayla, Rümeysa L Toraman et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, two-group pilot study assessed virtual reality (VR) during chemotherapy in 62 women who had undergone mastectomy. The intervention group watched videos using VR glasses; outcomes included salivary cortisol, state anxiety, pain, and vital signs measured around treatment. At the second assessment, anxiety, pain, and stress mean scores differed significantly between groups. Systolic and diastolic blood pressure also decreased significantly after chemotherapy in the VR group. The abstract reports statistical significance but provides no numerical effect sizes, cortisol values, or between-group estimates.

Key findings

  • At the second assessment, state anxiety and visual analog scale pain scores differed significantly between the VR and control groups.
  • Stress value mean scores differed significantly between groups at the second assessment.
  • Systolic and diastolic blood pressure decreased significantly after chemotherapy in the VR group.

Why it matters

Chemotherapy after breast surgery can involve pain, anxiety, and stress. This pilot trial suggests that a VR-based distraction during infusion may help address these symptoms and may also affect blood pressure. The findings provide preliminary evidence for a nonpharmacological supportive approach, while the abstract does not quantify the size of the observed differences.

What to keep in mind

This was a pilot study with 62 participants, and outcomes were assessed only before and immediately after chemotherapy; the abstract reports no effect sizes.

Source

Published in Cancer Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.